Capitalmind
Capitalmind

Archives

323 / 652

Premium

Macronomics: The First Sign of a Technical Long Term Downtrend

We write about the possibility of a long-term downtrend in the markets, by analyzing the Nifty. This post is for Capital Mind Premium subscribers ...
Charts & Analysis

Results Till Now: Nifty Companies See 11% Drop In Revenues, Profits as Cement Players Falter

Nifty Company results, till now, have had it rough, with a 11% drop in cumulative profits in the quarter, compared to last year. The worst performers have been ...
Premium

Portfolio: Market Beats Us Up, as we Exit the FMCG Ancilliary

Markets have continued their weakness and at this time we take notice of ...
Stocks

Infy: The Impact of Results on the Stock In The Past

As we approach Infy Results, we see that markets have been relatively benign about the company in recent times. While the stock shot up over 5% in Jan (after ...
Premium

Macronomics: Foreign Investors Are Slowly, But Steadily, Exiting Indian Markets

We write about the actions of Foreign investors in the Indian Debt and Equity markets. This post is for Capital Mind Premium subscribers ...
Economy

Government Says Let the Courts Decide the MAT Issue for FIIs

The government has refused to budge on the FII tax issue, it seems. Recently, the tax department had started to issue notices for Minimum Alternate Tax (MAT) ...
Stocks

Who Bought Those SunPharma Shares?

After that insane 20,000 cr. volume in Sun Pharma yesterday as Daiichi sold a whopping Rs. 20,000 cr.  worth shares, who really bought them? Turns out the ...
General

Trade Deficit Widens in March 2015, Total Trade Growth at Lowest Ever!

India’s Trade Deficit widened to $11.8 billion, which is the highest of the last four months (since November). Total imports fell 13% but exports fell ...
Premium

Macronomics: Three Sectors Showing Signs of Revival in Industial Production Data

 ...
Stocks

Daiichi Loses 20% on Selling Its Stake in Sun Pharma; Larger Questions on Market Liquidity Too

Sun Pharma has fallen 10% to 940 as Daiichi prepares to sell its stake of 214 million shares, on the stock exchanges. Daiichi acquired Ranbaxy at the price of ...